Therapeutic doses of antidepressants are projected not to inhibit human α4b2 nicotinic acetylcholine receptors

Neuropharmacology

Volumn 72, Issue , 2013, Pages 88-95

  Weber, Mark L ^a   Hofland, Corry M ^b   Shaffer, Christopher L ^a   Flik, Gunnar ^b   Cremers, Thomas ^b   Hurst, Raymond S ^a,d   Rollema, Hans ^c  

^a Pfizer Worldwide Research and Development   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c Rollema Biomedical Consulting   (United States)

^d AMGEN INC   (United States)

Author keywords

Antidepressants; Human unbound brain drug concentrations; Mecamylamine; Nortriptyline; Varenicline; 4b2 Nicotinic acetylcholine receptor

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CP 601927; FLUOXETINE; MECAMYLAMINE; NICOTINIC RECEPTOR ALPHA4BETA2; NORTRIPTYLINE; PAROXETINE; SERTRALINE; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN TISSUE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BINDING; DRUG BRAIN LEVEL; DRUG EFFICACY; HUMAN; IC 50; MALE; NONHUMAN; PATCH CLAMP; PHARMACOLOGICAL PARAMETERS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TREATMENT OUTCOME; UNBOUND PLASMA DRUG CONCENTRATION;

EID: 84884852407     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.04.027     Document Type: Article

References (56)

1. Al-Harbi, K.S., 2012. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer. Adherence 6, 369-388.
2. Arias, H.R., Bhumireddy, P., Bouzat, C., 2006. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int. J. Biochem. Cell. Biol. 38, 1254-1276.
3. Arias, H.R., Feuerbach, D., Targowska-Duda, K.M., Russell, M., Jozwiak, K., 2010. Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors. Biochemistry 49, 5734-5742.
4. Arias, H.R., Rosenberg, A., Targowska-Duda, K.M., Feuerbach, D., Jozwiak, K., Moaddel, R., Irving, W., Wainer, I.W., 2010b. Tricyclic antidepressants and mecamylamine bind to different sites in the human a4b2 nicotinic receptor ion channel. Int. J. Biochem. Cell. Biol. 42, 1007-1018.
5. Bacher, I., Wu, B., Shytle, D.R., George, T.P., 2009. Mecamylamine e a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. Expert. Opin. Pharmacother. 10, 2709-2721.
6. Bertrand, D., Picard, F., Le Hellard, S., Weiland, S., Favre, I., Phillips, H., Bertrand, S., Berkovic, S.F., Malafosse, A., Mulley, J., 2002. How mutations in the nAChRs can cause ADNFLE epilepsy. Epilepsia 43 (Suppl. 5), 112-122. (Pubitemid 34864217)
7. Bianchi, M.T., 2008. Non-serotonin anti-depressant actions: direct ion channel modulation by SSRIs and the concept of single agent poly-pharmacy. Med. Hypotheses 70, 951-956. (Pubitemid 351400707)
8. Borgå, O., Azarnoff, D.L., Forshell, G.P., Sjöqvista, F., 1969. Plasma protein binding of tricyclic antidepressants in man. Biochem. Pharmacol. 18, 2135-2143.
9. Chatterjee, S., Steensland, P., Simms, J.A., Holgate, J., Coe, J.W., Hurst, R.S., Shaffer, C.L., Low, J., Rollema, H., Bartlett, S.E., 2011. Partial agonists of the a3b4 neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats. Neuropsychopharmacology 36, 603-615.
10. Cremers, T.I., de Vries, M.G., Huinink, K.D., Van Loon, J.P., Van der Hart, M., Ebert, B., Westerink, Ben H.C., De Lange, E.C.M., 2009. Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique. J. Neurosci. Methods 178, 249-254.
11. Cremers, T.I., Flik, G., Hofland, C., Stratford, R.E., 2012. Microdialysis evaluation of clozapine and N-desmethylclozapine pharmacokinetics in rat brain. Drug. Metab. Dispos. 40, 1909-1916.
12. Derijks, H.J., Heerdink, E.R., Janknegt, R., De Koning, F.H.P., Olivier, B., Loonen, A.J.M., Egberts, A.C.G., 2008. Visualizing pharmacological activities of antidepressants: a novel approach. Open Pharmacol. J. 2, 54-62.
13. Di, L., Umland, J.P., Chang, G., Huang, Y., Lin, Z., Scott, D.O., Troutman, M.D., Liston, T.E., 2011. Species independence in brain tissue binding using brain homogenates. Drug. Metab. Dispos. 39, 1270-1277.
14. Doran, A.C., Osgood, S.M., Mancuso, J.Y., Shaffer, C.L., 2012. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab. Disp. 40, 2162-2173.
15. Dunbar, G.C., Kuchibhatla, R., Kumar, R., 2007. Mecamylamine in the treatment of depressed patients who were inadequate responders to citalopram first-line therapy; a double-blind placebo controlled add-on study. J. Psychopharmacol. 21, A40.
16. Fava, M., Ramey, T., Bell, J., Li, X., Boyer, S., Davidson, W., Billing, B., Arroyo, S., 2012. Augmenting SSRIs with an a4β2 nAChR partial agonist: lack of efficacy in insufficient response Major Depressive Disorder. Poster 31, ISCTM 8th Ann. Sci. Mtg., Washington, DC. https://isctm.org/public-access/Feb- 2012/22Feb2012-Posters-Abstracts.pdf.
17. Feuerbach, D., Lingenhohl, K., Dobbins, P., Mosbacher, J., Corbett, N., Nozulak, J., Hoyer, D., 2005. Coupling of human nicotinic acetylcholine receptors alpha7 to calcium channels in GH3 cells. Neuropharmacology 48, 215-227. (Pubitemid 40208257)
18. Fridén, M., Bergström, F., Wan, H., Rehngren, M., Ahlin, M., Hammarlund-Udenaes, M., Bredberg, U., 2011. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab. Disp. 39, 353-362.
19. Fryer, J.D., Lukas, R.J., 1999. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J. Neurochem. 72, 1117-1124. (Pubitemid 29085026)
20. George, T.P., Sacco, K.A., Vessicchio, J.C., Weinberger, A.H., Shytle, R.D., 2008. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitorrefractory major depressive disorder: a preliminary study. J. Clin. Psychopharmacol. 28, 340-344.
21. Giniatullin, R.A., Sokolova, E.M., Di Angelantonio, S., Skorinkin, A., Talantova, M.V., Nistri, A., 2000. Rapid relief of block by mecamylamine of neuronal nicotinic acetylcholine receptors of rat chromaffin cells in vitro: an electrophysiological and modeling study. Mol. Pharmacol. 58, 778-787.
22. Hughes, J.R., Stead, L.F., Lancaster, T., 1998. Antidepressants for smoking cessation. Cochrane Database Syst. Rev. 2007 (1). http://dx.doi.org/10. 1002/14651858.CD000031.pub3. Art. No.: CD000031.
23. Hurst, R.S., Rollema, H., Shaffer, C.L., Coe, J.W., Bertrand, D., 2012. Pharmacological profile of CP-601927 at neuronal nAChRs. Program No. 476.12/NN6.2012 Neuroscience Meeting Planner. New Orleans, LA, Soc. Neurosci. Online.
24. Institute for Laboratory Animal Resources, 1966. Guide for the Care and Use of Laboratory Animals, Commission on Life Sciences. NRC, Nat Acad Press, Washington D.C.
25. Janowsky, D.S., Davis, J.M., El-Yousef, M.K., Sekerke, H.J., 1972. Cholinergiceadrenergic hypothesis of mania and depression. Lancet 300, 632-635.
26. Kalvass, J.C., Maurer, T.S., 2002. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug. Dispos. 23, 327-338. (Pubitemid 36124162)
27. Kozikowski, A.P., Eaton, J.B., Bajjuri, K.M., Chellappan, S.K., Chen, Y., Karadi, S., He, R., Caldarone, B., Manzano, M., Yuen, P., Lukas, R.J., 2009. Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2- ylmethoxy)pyridin-3- yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression. Chem. Med. Chem. 4, 1279-1291.
28. Lippiello, P.M., Beaver, J.S., Gatto, G.J., James, J.W., Jordan, K.G., Traina, V.M., Xie, J., Bencherif, M., 2008. TC-5214 (S-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS. Neurosci. Ther. 14, 266-277.
29. Liu, X., Van Natta, K., Yeo, H., Vilenski, O., Weller, P.E., Worboys, P.D., Monshouwer, M., 2009. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug. Metab. Dispos. 37, 787-793.
30. López-Valdés, H.E., García-Colunga, J., 2001. Antagonism of nicotinic acetylcholine receptors by inhibitors of monoamine uptake. Mol. Psychiatry 6, 511-519. (Pubitemid 32772560)
31. Maurer, T.S., Debartolo, D.B., Tess, D.A., Scott, D.O., 2005. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug. Metab. Dispos. 33, 175-181. (Pubitemid 40023529)
32. Mineur, Y.S., Eibl, C., Young, G., Kochevar, C., Papke, R.L., Gündisch, D., Picciotto, M.R., 2009. Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J. Pharmacol. Exp. Ther. 329, 377-386.
33. Mineur, Y.S., Einstein, E.B., Seymour, P.A., Coe, J.W., O'Neill, B.T., Rollema, H., Picciotto, M.R., 2011. a4b2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties. Behav. Pharmacol. 22, 291-299.
34. Mineur, Y.S., Picciotto, M.R., 2010. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol. Sci. 31, 580-586.
35. Nierenberg, A.A., Papakostas, G.I., Petersen, T., Kelly, K.E., Iacoviello, B.M., Worthington, J.J., Tedlow, J., Alpert, J.E., Fava, M., 2003. Nortriptyline for treatment-resistant depression. J. Clin. Psychiatry 64, 35-39. (Pubitemid 36182227)
36. Papke, R.L., Sanberg, P.R., Shytle, R.D., 2001. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J. Pharmacol. Exp. Ther. 297, 646-656. (Pubitemid 32377996)
37. Pfizer: Chantix Safe for Smokers with Depression, 2012. Url: http://www. medpagetoday.com/PrimaryCare/Smoking/35384 (last accessed 12.01.12).
38. Philip, N.S., Carpenter, L.L., Tyrka, A.R., Price, L.H., 2010. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology (Berl) 212, 1-12.
39. Philip, N.S., Carpenter, L.L., Tyrka, A.R., Whiteley, L.B., Price, L.H., 2009. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J. Clin. Psychiatry 70, 1026-1031.
40. Power, R.A., Muthén, B., Henigsberg, N., Mors, O., Placentino, A., Mendlewicz, J., Maier, W., McGuffin, P., Lewis, C.M., Uher, R., 2012. Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder. J. Psychiatric Res. 46, 1333-1338.
41. Ramey, T., Bell, J., Boyer, S., 2012. Pharmacological and clinical profile of CP- 601,927: evidence for activity at the nAChR site. Program No. 780.11/KK7.2012 Neuroscience Meeting Planner. New Orleans, LA, Soc. Neurosci. Online.
42. Remaining TC-5214 Phase III efficacy studies do not meet endpoint, regulatory filing will not be pursued. Url: http://www.reuters.com/article/2011/ 11/08/astrazenecatargacept- idUSL6-7M80SI20111108? typecompanyNews&feedTypeRSS&feed NamecompanyNews&rpc43 (last accessed 12.01.12).
43. Rollema, H., Chambers, L.K., Coe, J.W., Glowa, J., Hurst, R.S., Lebel, L.A., Lu, Y., Mansbach, R.S., Mather, R.J., Rovetti, C.C., Sands, S.B., Schaeffer, E., Schulz, D.W., Tingley III, F.D., Williams, K.E., 2007. Pharmacological profile of the a4b2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52, 985-994. (Pubitemid 46227486)
44. Rollema, H., Guanowsky, V., Mineur, Y.S., Shrikhande, A., Coe, J.W., Seymour, P.A., Picciotto, M.R., 2009. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur. J. Pharmacol. 605, 114-116.
45. Rollema, H., Shrikhande, A., Ward, K.M., Tingley, F.D., Coe, J.W., O'Neill, B.T., Tseng, E., Wang, E.Q., Mather, R.J., Hurst, R.S., Williams, K.E., De Vries, M., Cremers, T., Bertrand, S., Bertrand, D., 2010. Pre-clinical properties of the a4b2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br. J. Pharmacol. 160, 334-345.
46. Saricicek, A., Esterlis, I., Maloney, K.H., Mineur, Y.S., Ruf, B.M., Muralidharan, A., Chen, J.I., Cosgrove, K.P., Kerestes, R., Ghose, S., Tamminga, C.A., Pittman, B., Bois, F., Tamagnan, G., Seibyl, J., Picciotto, M.R., Staley, J.K., Bhagwagar, Z., 2012. Persistent b2-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am. J. Psychiatry 169, 851-859.
47. Shaffer, C.L., 2010. Defining neuropharmacokinetic parameters in CNS drug discovery to determine cross-species pharmacologic exposureeresponse relationships. Ann. Rep. Med. Chem. 45, 55-70.
48. Shytle, R.D., Silver, A.A., Lukas, R.J., Newman, M.B., Sheehan, D.V., Sanberg, P.R., 2002. Nicotinic acetylcholine receptors as targets for antidepressants. Mol. Psychiatry 7, 525-535.
49. Summerfield, S.G., Read, K., Begley, D.J., Obradovic, T., Hidalgo, I.J., Coggon, S., Lewis, A.V., Porter, R.A., Jeffrey, P., 2007. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 322, 205-213. (Pubitemid 46956363)
50. Tammimäki, A., Herder, P., Li, P., Esch, C., Laughlin, J.R., Akk, G., Stitzel, J.A., 2012. Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by a3b4a5 nicotinic acetylcholine receptors. Neuropharmacology 63, 1002-1011.
51. Targacept presents data from highly successful Phase 2b trial of TC-5214 as augmentation treatment for Major Depressive Disorder. Url: http://www. targacept.com/wt/page/pr-1255642681 (last accessed 12.01.12).
52. Thummel, K.E., Shen, D.D., Isoherranen, N., 2011. Design and optimizations of dosage regimens: pharmacokinetic data. In: Brunton, L., Chabner, B., Knollman, B. (Eds.), Goodman & Gilman's the Pharmacological Basis of Therapeutics, 12th ed. McGraw-Hill, New York, pp. 1891-1990.
53. Tillement, J.-P., Urien, S., Chaumet-Riffaud, P., Riant, P., Bree, F., Morin, D., et al., 1988. Blood binding and tissue uptake of drugs. Recent advances and perspectives. Fundam. Clin. Pharmacol. 2, 223-238.
54. Tsai, S.-J., Yeh, H.-L., Hong, C.-J., Liou, Y.-J., Yang, A.C., Liu, M.-E., Hwang, J.-P., 2012. Association of CHRNA4 polymorphism with depression and loneliness in elderly males. Genes Brain Behav. 11, 230-234.
55. Young, J.M., Shytle, R.D., Sanberg, P.R., George, T.P., 2001. Mecamylamine: new therapeutic uses and toxicity/risk profile. Clin. Ther. 23, 532-565. (Pubitemid 32411406)
56. Zhang, H., Tückmantel, W., Eaton, J.B., Yuen, P.W., Yu, L.F., Bajjuri, K.M., Fedolak, A., Wang, D., Ghavami, A., Caldarone, B., Paterson, N.E., Lowe, D.A., Brunner, D., Lukas, R.J., Kozikowski, A.P., 2012. Chemistry and behavioral studies identify chiral cyclopropanes as selective a4b2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile. J. Med. Chem. 55, 717-724.